Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06598514 · ClinicalTrials.gov registry record · Phase 4
Chlorhexidine Lavage for Recurrent Urinary Tract Infection
A Phase 4 study of Urinary Tract Infections and Recurrent Urinary Tract Infection, sponsored by Oregon Health and Science University.
- Active
- Registry status
- Phase 4
- Development phase
- 136
- Enrollment target
- 1
- Study location
NCT06598514: Active Phase 4 study of Urinary Tract Infections and Recurrent Urinary Tract Infection, sponsored by Oregon Health and Science University.
NCT06598514 is a Phase 4 study of Urinary Tract Infections and Recurrent Urinary Tract Infection that is active but no longer recruiting, run by Oregon Health and Science University. The registered enrollment target is 136 participants, below the 454-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06598514, a Phase 4 study of Urinary Tract Infections and Recurrent Urinary Tract Infection, is active but no longer recruiting, sponsored by Oregon Health and Science University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 136 participants
- Enrollment target
- 1
- Study location
Study Summary
A two-arm randomized control trial evaluating rates of urinary tract infection in post-menopausal women on vaginal estrogen with recurrent urinary tract infections.
Primary Outcome
The proportion of participants in each arm who experience a urinary tract infection (UTI) within 90 days will be compared
Conditions Studied
Interventions
- DRUG Chlorhexidine
- DRUG Sterile Water
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2024-12-23 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
What the registry record for NCT06598514 still lists
NCT06598514 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 454-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Urinary Tract Infections appearing as the primary indexed condition, and to 2 interventions - of which Chlorhexidine is the first listed.
NCT06598514 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT06598514 about?
NCT06598514 is a clinical study titled "Chlorhexidine Lavage for Recurrent Urinary Tract Infection". A two-arm randomized control trial evaluating rates of urinary tract infection in post-menopausal women on vaginal estrogen with recurrent urinary tract infections.
What is the current status of trial NCT06598514?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 136 participants. The study started on 2024-12-23. Estimated completion is 2026-06.
What conditions does trial NCT06598514 study?
This clinical trial studies the following conditions: Urinary Tract Infections, Recurrent Urinary Tract Infection.
What interventions are being tested in trial NCT06598514?
The interventions under investigation include: Chlorhexidine (DRUG), Sterile Water (DRUG).
Who is sponsoring clinical trial NCT06598514?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06598514 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Tract Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06598514's enrollment target sits among peer trials
136 21st of 34 higher than 13 of 34 other Urinary Tract Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urinary Tract Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NextGen - Clinical Implication of Next Generation Sequencing
RECRUITING · Phase 4
-
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
RECRUITING · Phase 1
-
Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting
RECRUITING · NA
-
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
RECRUITING · NA
-
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
RECRUITING
-
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI